Familial and sporadic Alzheimer's disease: Neuropathology cannot exclude a final common pathway

C. F. Lippa, A. M. Saunders, T. W. Smith, J. M. Swearer, D. A. Drachman, B. Ghetti, L. Nee, D. Pulaski-Salo, Dennis W Dickson, Y. Robitaille, C. Bergeron, B. Crain, M. D. Benson, M. Farlow, B. T. Hyman, P. St. George-Hyslop, A. D. Roses, D. A. Pollen

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Whether all etiologic forms of Alzheimer's disease (AD) share a final common pathway is a major issue. We determined the severity and regional distribution of neuronal loss, amyloid plaques, neuritic plaques (NPs), and neurofibrillary tangles (NFTs), and calculated the ratio of neuronal loss to NPs and NFTs in brains of 19 familial AD (FAD) patients with linkage to chromosome 14, six AD patients with mutations of chromosome 21 (codon 717 of the β-amyloid precursor protein gene), and 11 sporadic AD (SAD) patients. There was no difference in the pattern of distribution of the various pathologic features or in the ratio of neuronal loss to NPs or NFTs in any AD group. However, FAD groups could be distinguished from SAD by the greater severity and the lack of influence of apolipoprotein E genotype on pathology. These differences may reflect differences in age at onset rather than different etiopathologic mechanisms. The similarity of pathologic findings in the different AD groups provides evidence for a final common pathophysiologic pathway in AD.

Original languageEnglish (US)
Pages (from-to)406-412
Number of pages7
JournalNeurology
Volume46
Issue number2
StatePublished - Feb 1996
Externally publishedYes

Fingerprint

Alzheimer Disease
Amyloid Plaques
Neurofibrillary Tangles
Chromosomes, Human, Pair 14
Chromosomes, Human, Pair 21
Amyloid beta-Protein Precursor
Apolipoproteins E
Age of Onset
Codon
Neuropathology
Genotype
Pathology
Mutation
Brain
Genes

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Lippa, C. F., Saunders, A. M., Smith, T. W., Swearer, J. M., Drachman, D. A., Ghetti, B., ... Pollen, D. A. (1996). Familial and sporadic Alzheimer's disease: Neuropathology cannot exclude a final common pathway. Neurology, 46(2), 406-412.

Familial and sporadic Alzheimer's disease : Neuropathology cannot exclude a final common pathway. / Lippa, C. F.; Saunders, A. M.; Smith, T. W.; Swearer, J. M.; Drachman, D. A.; Ghetti, B.; Nee, L.; Pulaski-Salo, D.; Dickson, Dennis W; Robitaille, Y.; Bergeron, C.; Crain, B.; Benson, M. D.; Farlow, M.; Hyman, B. T.; St. George-Hyslop, P.; Roses, A. D.; Pollen, D. A.

In: Neurology, Vol. 46, No. 2, 02.1996, p. 406-412.

Research output: Contribution to journalArticle

Lippa, CF, Saunders, AM, Smith, TW, Swearer, JM, Drachman, DA, Ghetti, B, Nee, L, Pulaski-Salo, D, Dickson, DW, Robitaille, Y, Bergeron, C, Crain, B, Benson, MD, Farlow, M, Hyman, BT, St. George-Hyslop, P, Roses, AD & Pollen, DA 1996, 'Familial and sporadic Alzheimer's disease: Neuropathology cannot exclude a final common pathway', Neurology, vol. 46, no. 2, pp. 406-412.
Lippa CF, Saunders AM, Smith TW, Swearer JM, Drachman DA, Ghetti B et al. Familial and sporadic Alzheimer's disease: Neuropathology cannot exclude a final common pathway. Neurology. 1996 Feb;46(2):406-412.
Lippa, C. F. ; Saunders, A. M. ; Smith, T. W. ; Swearer, J. M. ; Drachman, D. A. ; Ghetti, B. ; Nee, L. ; Pulaski-Salo, D. ; Dickson, Dennis W ; Robitaille, Y. ; Bergeron, C. ; Crain, B. ; Benson, M. D. ; Farlow, M. ; Hyman, B. T. ; St. George-Hyslop, P. ; Roses, A. D. ; Pollen, D. A. / Familial and sporadic Alzheimer's disease : Neuropathology cannot exclude a final common pathway. In: Neurology. 1996 ; Vol. 46, No. 2. pp. 406-412.
@article{a6b8706a1d99402db36eae5af0a1df99,
title = "Familial and sporadic Alzheimer's disease: Neuropathology cannot exclude a final common pathway",
abstract = "Whether all etiologic forms of Alzheimer's disease (AD) share a final common pathway is a major issue. We determined the severity and regional distribution of neuronal loss, amyloid plaques, neuritic plaques (NPs), and neurofibrillary tangles (NFTs), and calculated the ratio of neuronal loss to NPs and NFTs in brains of 19 familial AD (FAD) patients with linkage to chromosome 14, six AD patients with mutations of chromosome 21 (codon 717 of the β-amyloid precursor protein gene), and 11 sporadic AD (SAD) patients. There was no difference in the pattern of distribution of the various pathologic features or in the ratio of neuronal loss to NPs or NFTs in any AD group. However, FAD groups could be distinguished from SAD by the greater severity and the lack of influence of apolipoprotein E genotype on pathology. These differences may reflect differences in age at onset rather than different etiopathologic mechanisms. The similarity of pathologic findings in the different AD groups provides evidence for a final common pathophysiologic pathway in AD.",
author = "Lippa, {C. F.} and Saunders, {A. M.} and Smith, {T. W.} and Swearer, {J. M.} and Drachman, {D. A.} and B. Ghetti and L. Nee and D. Pulaski-Salo and Dickson, {Dennis W} and Y. Robitaille and C. Bergeron and B. Crain and Benson, {M. D.} and M. Farlow and Hyman, {B. T.} and {St. George-Hyslop}, P. and Roses, {A. D.} and Pollen, {D. A.}",
year = "1996",
month = "2",
language = "English (US)",
volume = "46",
pages = "406--412",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Familial and sporadic Alzheimer's disease

T2 - Neuropathology cannot exclude a final common pathway

AU - Lippa, C. F.

AU - Saunders, A. M.

AU - Smith, T. W.

AU - Swearer, J. M.

AU - Drachman, D. A.

AU - Ghetti, B.

AU - Nee, L.

AU - Pulaski-Salo, D.

AU - Dickson, Dennis W

AU - Robitaille, Y.

AU - Bergeron, C.

AU - Crain, B.

AU - Benson, M. D.

AU - Farlow, M.

AU - Hyman, B. T.

AU - St. George-Hyslop, P.

AU - Roses, A. D.

AU - Pollen, D. A.

PY - 1996/2

Y1 - 1996/2

N2 - Whether all etiologic forms of Alzheimer's disease (AD) share a final common pathway is a major issue. We determined the severity and regional distribution of neuronal loss, amyloid plaques, neuritic plaques (NPs), and neurofibrillary tangles (NFTs), and calculated the ratio of neuronal loss to NPs and NFTs in brains of 19 familial AD (FAD) patients with linkage to chromosome 14, six AD patients with mutations of chromosome 21 (codon 717 of the β-amyloid precursor protein gene), and 11 sporadic AD (SAD) patients. There was no difference in the pattern of distribution of the various pathologic features or in the ratio of neuronal loss to NPs or NFTs in any AD group. However, FAD groups could be distinguished from SAD by the greater severity and the lack of influence of apolipoprotein E genotype on pathology. These differences may reflect differences in age at onset rather than different etiopathologic mechanisms. The similarity of pathologic findings in the different AD groups provides evidence for a final common pathophysiologic pathway in AD.

AB - Whether all etiologic forms of Alzheimer's disease (AD) share a final common pathway is a major issue. We determined the severity and regional distribution of neuronal loss, amyloid plaques, neuritic plaques (NPs), and neurofibrillary tangles (NFTs), and calculated the ratio of neuronal loss to NPs and NFTs in brains of 19 familial AD (FAD) patients with linkage to chromosome 14, six AD patients with mutations of chromosome 21 (codon 717 of the β-amyloid precursor protein gene), and 11 sporadic AD (SAD) patients. There was no difference in the pattern of distribution of the various pathologic features or in the ratio of neuronal loss to NPs or NFTs in any AD group. However, FAD groups could be distinguished from SAD by the greater severity and the lack of influence of apolipoprotein E genotype on pathology. These differences may reflect differences in age at onset rather than different etiopathologic mechanisms. The similarity of pathologic findings in the different AD groups provides evidence for a final common pathophysiologic pathway in AD.

UR - http://www.scopus.com/inward/record.url?scp=9044239670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9044239670&partnerID=8YFLogxK

M3 - Article

C2 - 8614503

AN - SCOPUS:9044239670

VL - 46

SP - 406

EP - 412

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 2

ER -